anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

199,141-199,200 of 319,975

filter-aware
15
Comera | Investor Presentation Deck | 22 slidesComera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
16
The DLS screen shows hydrodynamic radius (Rh) over time for various buffers; the accelerated stress screen compares 0-week vs 2-week stability across four buffer conditions.Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
17
The slide displays three distinct charts: two BLI sensorgrams (top left and bottom left) and one viscosity vs concentration scatter plot (right).Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
18
The slide demonstrates a progression from initial screening (DLS) to final stability assessment (monomer loss) to justify the selection of specific excipient combinations.Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
19
Includes a scatter plot, bar chart, line chart, and summary table comparing different stabilizer mixtures.Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
20
Includes a bar chart of DOE samples, a linear regression plot of pH vs monomer, and a heatmap of sugar vs pH.Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
21
Comera | Investor Presentation Deck | 22 slidesComera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
22
Comera | Investor Presentation Deck | 22 slidesComera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
01
Slide 1
Features a molecular visualization with a target reticle.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
02
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a ribbon-style list format to categorize key company information.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The chart uses a horizontal bar format to represent the development stage of various drug candidates.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The slide uses a grid layout to display headshots, names, titles, and a collection of logos representing past or associated company experience.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide features a compass-like icon, suggesting a navigational or strategic focus for the upcoming section.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
07
The slide illustrates the mechanism of action of a bispecific antibody targeting DLL4 and VEGF-A.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
MTD = Maximum Tolerated Dose; PR = Partial Response; RECIST = Response Evaluation Criteria in Solid Tumors; ORR = Objective Response Rate.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
The chart displays tumor growth percentages for individual patients, categorized by cancer type (Gastric, CRC, Other) and labeled with dosage (mpk).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The table highlights Partial Response (PR) rates with a red border.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
The chart highlights a subset of patients with significant tumor reduction (boxed area).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
Includes footnotes regarding clinical trial context for hypertension and cytopenia.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
14
The slide presents clinical efficacy data comparing monotherapy vs combination therapy across two metrics.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The slide illustrates a standard Simon 2-Stage design, a common statistical framework for Phase II oncology trials.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
16
The table highlights patient age, gender, ECOG status, prior therapies, and cancer subtypes.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
17
This is a standard oncology 'swimmer's plot' or 'waterfall plot' used to demonstrate clinical efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
18
Standard clinical trial swimmer plot visualization.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
19
Includes patient enrollment status and breakdown of ORR by prior lines of therapy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
20
Standard clinical trial survival analysis charts (Kaplan-Meier) with 'Number at risk' tables below.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
The slide compares clinical trial data for a specific combination therapy against historical label data for individual components.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
The table compares a small sample size (N=24) against much larger historical cohorts.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
23
The slide uses a side-by-side comparison to highlight the superior ORR, PFS, and OS of CTX-009 compared to historical benchmarks like FOLFOX and TOPAZ-1.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
24
The slide outlines a 2:1 randomized clinical trial structure for a drug combination (CTX-009 + Paclitaxel) versus a control (Paclitaxel).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
25
The slide uses a table for market sizing and a structured layout to contrast 1L and 2L treatment options.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
26
The slide depicts a standard Simon 2-stage design, a common statistical framework in oncology clinical trials.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
27
The slide provides epidemiological data alongside a clinical treatment landscape overview.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
28
The slide uses a three-column layout to represent sequential or parallel development tracks.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
29
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
30
Includes a molecular visualization showing the binding site of CTX-471 compared to other antibodies.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
31
The slide uses a before-and-after visual comparison of CT scans to demonstrate drug efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
32
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
33
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
34
The slide uses a process flow diagram to show the transition from testing bispecific formats to the identification of the lead candidate CTX-8371.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
35
The slide uses a visual comparison framework to contrast standard therapy (left) with the company's proprietary mechanism (right).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
36
The slide shows tumor volume reduction over time, percentage tumor growth inhibition, and individual tumor response curves, highlighting CTX-8371's efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
37
The slide outlines the current progress and future clinical trial design for a drug candidate.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
38
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
39
The slide uses a list-based structure to summarize drug development progress across three distinct assets.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
40
The timeline uses blue and red color coding for different drug programs or status types.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
01
Slide 1
Coupang | Results Presentation Deck | 16 slidesCoupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations 1 hit
02
Coupang | Results Presentation Deck | 16 slidesCoupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations 1 hit
03
Coupang | Results Presentation Deck | 16 slidesCoupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations 1 hit
04
The chart uses a bubble-based growth visualization to represent market size expansion.Coupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations Beat · Market Size1 hit
05
The table uses a stair-step visual representation to highlight the compounding nature of cohort spending.Coupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
06
The chart uses a line graph to visualize cohort retention and expansion over time.Coupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
07
Data points represent millions of members at the end of each quarter.Coupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
08
The chart illustrates the scale of fulfillment and logistics centers in Korea.Coupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
09
Highlights 2020 and 2021 as 'Covid Years' with a visual overlay.Coupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
10
Coupang | Results Presentation Deck | 16 slidesCoupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
11
The slide highlights the company's financial trajectory and strategic levers for cash flow improvement.Coupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
12
Coupang | Results Presentation Deck | 16 slidesCoupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations 1 hit